Lee Ainslie Bei Gene, Ltd. Transaction History

Maverick Capital LTD

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $880,838 - $1.42 Million	-3,529 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$292.75 - $367.01 $19,321 - $24,222	66 Added 1.91%	3,529 $1.21 Million
Q1 2021 May 17, 2021	BUY	$260.64 - $382.12 $902,596 - $1.32 Million	3,463 New	3,463 $1.21 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.9B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.